Company / Cash per Share
RAPT Therapeutics, Inc. Cash per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$4.16
FY2024
5-year range
$0.88 / $4.16
FY2020-FY2024
Trend
+236.3%
vs FY2023
Sector context
#51 of 203
Health Care
What the data says
Cash per Share changed +236% YoY in FY2024, a notable deviation from the 6-year average annual change of +14%.
Based on SEC 10-K filings.
4.16 in FY2024 with a 5-year CAGR of -25.2%. Top quartile in the Health Care sector.
Improved from $1.20 to $4.16 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +68.1%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 203This company $4.16 Sector average $76.43
▼
-94.6% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s cash per share has grown for 3 consecutive years.
- In FY2024, cash per share increased 236.3% year-over-year.
- Ranks #51 out of 203 companies in the Health Care sector.
- Peak cash per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $4.16 | +236.3% |
| FY2023 | $1.24 | +3.5% |
| FY2022 | $1.20 | +36.4% |
| FY2021 | $0.88 | -15.0% |
| FY2020 | $1.03 | -94.2% |
| FY2019 | $17.80 | -82.6% |
| FY2018 | $102.52 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026